Scarica l'app Stockscreener
0.655
9.75%
0.0582
Pre-mercato:
.66
0.005
+0.76%
Precedente Chiudi:
$0.5968
Aprire:
$0.5998
Volume 24 ore:
8.90M
Relative Volume:
0.49
Capitalizzazione di mercato:
$90.02M
Reddito:
-
Utile/perdita netta:
$-12.89M
Rapporto P/E:
-0.2589
EPS:
-2.53
Flusso di cassa netto:
$-11.95M
1 W Prestazione:
+9.48%
1M Prestazione:
+28.61%
6M Prestazione:
+85.71%
1 anno Prestazione:
-50.75%
Intervallo 1D:
$0.5998
$0.66
Intervallo di 1 settimana:
$0.55
$0.66
Portata 52W:
$0.1634
$2.3099
Plus Therapeutics Inc Stock (PSTV) Company Profile
Nome
Plus Therapeutics Inc
Settore
Industria
Telefono
737.255.7194
Indirizzo
4200 MARATHON BLVD., AUSTIN, TX
Confronta PSTV con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PSTV
Plus Therapeutics Inc
|
0.655 | 82.02M | 0 | -12.89M | -11.95M | -2.53 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.26 | 117.50B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.83 | 76.06B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.56 | 62.53B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
916.31 | 56.75B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
205.04 | 44.10B | 447.02M | -1.18B | -906.14M | -6.1812 |
Plus Therapeutics Inc Stock (PSTV) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-09-03 | Aggiornamento | D. Boral Capital | Hold → Buy |
| 2025-03-17 | Iniziato | D. Boral Capital | Buy |
| 2021-01-25 | Iniziato | Ladenburg Thalmann | Buy |
| 2020-10-16 | Iniziato | Maxim Group | Buy |
Plus Therapeutics Inc Borsa (PSTV) Ultime notizie
Why global investors buy Plus Therapeutics Inc. (XMP0) stock2025 Price Targets & Free Verified High Yield Trade Plans - Newser
Hines Adds 3 Life-Science Tenants at Levit Green - Realty News Report
Hines' Levit Green signs 3 biotech tenants for 30K-SF of lab and office space - The Business Journals
Plus Therapeutics Highlights Three REYOBIQ™ Clinical Data Presentations at 2025 WFNOS/SNO Annual Meeting - The Manila Times
Will Plus Therapeutics Inc. (XMP0) stock rise with strong economyTrade Ideas & Precise Buy Zone Tips - Newser
How Plus Therapeutics Inc. stock reacts to Fed rate cutsIPO Watch & Technical Entry and Exit Tips - Newser
Will Plus Therapeutics Inc. (XMP0) stock beat Nasdaq index returns2025 Analyst Calls & Smart Allocation Stock Reports - Newser
Plus Therapeutics' (PSTV) Buy Rating Reiterated at D. Boral Capital - MarketBeat
Aug Highlights: How Plus Therapeutics Inc. stock performs in weak economyMarket Sentiment Summary & Smart Allocation Stock Reports - BỘ NỘI VỤ
Will Plus Therapeutics Inc. stock gain from lower inflationTrade Signal Summary & High Accuracy Trade Alerts - Newser
How higher bond yields impact Plus Therapeutics Inc. (XMP0) stock2025 Breakouts & Breakdowns & Weekly Market Pulse Updates - Newser
How dovish Fed policy supports Plus Therapeutics Inc. (XMP0) stock2025 Price Action Summary & Risk Controlled Daily Trade Plans - Newser
Why Plus Therapeutics Inc. stock is favored by top institutions - Newser
D. Boral Capital Maintains Plus Therapeutics (PSTV) Buy Recommendation - Nasdaq
Plus Therapeutics (PSTV) Analyst Rating Update: Maintain Buy Rat - GuruFocus
Plus Therapeutics to present breast cancer treatment data at SABCS By Investing.com - Investing.com Nigeria
Plus Therapeutics to present breast cancer treatment data at SABCS - Investing.com
Plus Therapeutics to Present ReSPECT Phase 1 Dose Escalation Study Results for Leptomeningeal Metastases at the 2025 San Antonio Breast Cancer Symposium - The Manila Times
Plus Therapeutics, Inc. Announces Abstract Acceptance for Spotlight Presentation at San Antonio Breast Cancer Symposium 2025 on Rhenium (186Re) obisbemeda for Leptomeningeal Metastases Treatment - Quiver Quantitative
Plus Therapeutics (NASDAQ: PSTV) lands SABCS 2025 spotlight for LM Phase 1 trial - Stock Titan
How Plus Therapeutics Inc. stock reacts to job market dataFed Meeting & Long Hold Capital Preservation Tips - moha.gov.vn
Plus Therapeutics Eyes Expansion Despite Wider Quarterly Loss - Finimize
H.C. Wainwright reaffirms Buy rating on Plus Therapeutics stock at $2.00 - Investing.com Nigeria
H.C. Wainwright reaffirms Buy rating on Plus Therapeutics stock at $2.00 By Investing.com - Investing.com India
PSTV Stock on November 25, 2025: FDA Meeting, Nasdaq Extension and Humana Deal Put Plus Therapeutics Back in Focus - ts2.tech
Plus Therapeutics completes FDA meeting on REYOBIQ cancer treatment - Investing.com India
Plus Therapeutics completes FDA meeting on REYOBIQ cancer treatment By Investing.com - Investing.com Nigeria
Plus Therapeutics (PSTV) Advances Reyobiq Development After FDA Meeting - GuruFocus
Plus Therapeutics Announces Completion of U.S. FDA Meeting on Future Clinical Development Plans for REYOBIQ™ in Leptomeningeal Metastases - The Manila Times
Plus Therapeutics Announces Completion of U.S. FDA Meeting - GlobeNewswire
Plus Therapeutics Stock (PSTV) Opinions on Humana Coverage Agreement - Quiver Quantitative
Ascendiant Capital Maintains Plus Therapeutics (PSTV) Buy Recommendation - Nasdaq
Plus Therapeutics (PSTV) Maintains Buy Rating, Lowers Price Targ - GuruFocus
Will Plus Therapeutics Inc. (XMP0) stock outperform global peersWeekly Earnings Recap & Real-Time Chart Breakout Alerts - newser.com
Can Plus Therapeutics Inc. stock withstand economic slowdownJuly 2025 Analyst Calls & Daily Technical Forecast Reports - newser.com
Plus Therapeutics, Inc. (PSTV) Stock: Hits Highs as CNSide Gains National Coverage - parameter.io
Plus Therapeutics shares climb after subsidiary secures nationwide Humana coverage - MSN
PSTV: D. Boral Capital Maintains Buy Rating and $5.00 Price Target | PSTV Stock News - GuruFocus
Plus Therapeutics stock rises after subsidiary signs Humana agreement By Investing.com - Investing.com Nigeria
Plus Therapeutics stock rises after subsidiary signs Humana agreement - Investing.com
Plus Therapeutics secures national coverage agreement with Humana for CNSide® cerebrospinal fluid assay for metastatic CNS cancer - MarketScreener
Is Plus Therapeutics Inc. stock ready for breakoutWeekly Risk Report & AI Powered Buy and Sell Recommendations - newser.com
Will Plus Therapeutics Inc. (XMP0) stock issue positive guidancePortfolio Gains Summary & Fast Exit Strategy with Risk Control - newser.com
Plus Therapeutics Secures National Coverage Agreement with Humana for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer - The Manila Times
Plus Therapeutics (NASDAQ: PSTV) Humana agreement lifts CNSide assay coverage to 67M - Stock Titan
How Plus Therapeutics Inc. (XMP0) stock moves on employment dataQuarterly Market Review & Low Volatility Stock Recommendations - newser.com
Is Plus Therapeutics Inc. (XMP0) stock a buy on weaknessJuly 2025 Pullbacks & Proven Capital Preservation Tips - newser.com
Plus Therapeutics Inc Azioni (PSTV) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.10%
1.10%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):